from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. A human monoclonal antibody which is being studied in the treatment of bone disorders such as osteoporosis.


from Wiktionary, Creative Commons Attribution/Share-Alike License

Ad hoc prefix + -os- + -u- + -mab


  • The study compared Prolia, also known by its generic name denosumab, with Zometa, a

    Amgen Drug Shown to Delay Fractures in Cancer Patients

  • The disappointing revenue numbers for the Thousand Oaks, Calif., company -- highlighted by a 20% decline in sales of arthritis drug Enbrel -- increases the stakes for the success of Amgen's experimental bone drug denosumab, which is expected to get an approval decision from the Food and Drug Administration in October.

    Amgen Curbs Its Projection for Revenue

  • The new drug, called denosumab, or D-mab, was previously shown to increase bone mass in people at risk for the brittle-bone disease osteoporosis.

    Amgen Bone-Building Drug

  • The news comes on the back of the success of a study of its lead drug candidate, bone-loss drug denosumab, which is hoped to reinvigorate growth at the company, overcoming the stagnant growth of its EPO anemia drugs -- Aranesp and Epogen.

    Amgen's Profit Declines 7.7%

  • Critical to Amgen's plans is gaining regulatory approval for its experimental bone-strengthening drug, called denosumab, and launching it successfully in an already crowded $7 billion global market for osteoporosis treatments.

    Amgen Anemia-Drug Woes Will Bottom Out, Chief Says

  • Food and Drug Administration cleared the drug, also known as denosumab, to reduce fracture risks in breast cancer patients taking drugs that halt estrogen production and prostate cancer patients treated with androgen-deprivation therapies, Thousand Oaks, California-based Amgen said today in a statement.

  • WEDNESDAY, Feb. 23 (HealthDay News) -- A new drug called denosumab (Xgeva) performed somewhat better than the current standard treatment of zoledronic acid (Zometa) for preventing fractures and other bone problems in men with hormone-resistant prostate cancer, a new study suggests.

    Yahoo! News: Business - Opinion

  • Yesterday Amgen released positive results from its third phase 3 trial pitting Prolia (aka denosumab) against Novartis '(NYSE: NVS) Zometa in prostate cancer patients whose tumors had spread to the bone. The Motley Fool

  • The biotechnology firm announced that a much-awaited study of its bone drug Xgeva also known as denosumab, and sold for osteoporosis as Prolia prevented prostate cancer from spreading to the bone in patient whose levels of prostate-specific antigen are rising.

    Amgen Drug Prevents Prostate Cancer From Spreading To Bone - Matthew Herper - The Medicine Show - Forbes

  • Thousand Oaks, Calif. -based Amgen saw its stock price rise about 24 percent in 2008 as it rolled out a steady beat of positive clinical trial data on denosumab, which is now under Food and Drug Administration review. - News


Log in or sign up to get involved in the conversation. It's quick and easy.